검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 3개 · 임상 갱신 필요 1개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Fluorouracil (Fluorouracil) Janssen Research & Development, LL…·Muscle Invasive Bladder Carcinoma ORR 80% | ||
|---|---|---|---|
Overview Program | Fluorouracil | Tremelimumab | MK-3475 |
Overview Company | Janssen Research & Development, LLC | AstraZeneca | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | Muscle Invasive Bladder Carcinoma | Muscle Invasive Bladder Cancer | Bladder Cancer |
Overview Indication | Advanced or Metastatic Colorectal Cancer | Hepatocellular Carcinoma | Melanoma; Non-Small Cell Lung Cancer |
Overview Phase | PHASE_3 | PHASE_3 | PHASE_2 |
Overview Status | RECRUITING | RECRUITING | RECRUITING |
MoA Mechanism | inhibits GC cell proliferation and induces apoptosis by regulating cell-cycle checkpoints and inhibiting oncogenic pathway | targeting antigens like GPC3, AFP, and PD-L1, have been engineered to address antigen | — |
MoA Biomarker | biomarker for metabolic state, B-cell/TLS-associated immune features, and vulnerability to DNA damage-based t | biomarkers for dual immune checkpoint blockade remain insufficiently defined | PD-L1) combined positive |
PK/PD Half-life | — | 16.9 h | 3 h |
PK/PD Species | Mouse, Rabbit | Mouse | Cynomolgus monkey, NHP, Mouse |
PK/PD Animal (cat.) | Mouse | Mouse | Mouse, NHP, Monkey, In vitro |
PK/PD Experiment | pharmacokinetic | PD | PD |
Toxicology Species | Rabbit | Mouse | Cynomolgus monkey, NHP, Mouse |
Toxicology Animal (cat.) | Unknown | Mouse | Mouse, NHP, Monkey, In vitro |
Toxicology Major finding | Green synthesized cobalt doped graphene quantum dots derived from Boswellia serrata for dual ligand targeted bioimaging and delivery of exemestane.. Major objective of hydrothermal method is to achieve the synthesis of Cobalt doped Graphene quantum dots (Co-GQDs) using natural precursor (Boswellia serrata gum resin). The Co-GQDs were surface engineered with folic acid (FA) and hyaluronic acid (HA)… | Interstitial lung disease associated with novel anticancer agents in non-small cell lung cancer: | pneumonitis) after switching were explored |
Clinical Primary efficacy | ORR 80% | ORR 84.6% | ORR 38% |
Clinical ORR | 80.0% | 84.6% | 38% |
Clinical Result source | ClinicalTrials.gov NCT04430738 | ClinicalTrials.gov NCT03043872 | ClinicalTrials.gov NCT02444741 |
Clinical Data Tier / Score | S · 70 | B · 70 | C · 47 |
Clinical Program phase | PHASE_3 | PHASE_3 | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) | 2026년 7월 18일 (8일 전) | 2026년 7월 9일 (18일 전 · 갱신 권장) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 3개 · 임상 갱신 필요 1개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Fluorouracil (Fluorouracil) Janssen Research & Development, LL…·Muscle Invasive Bladder Carcinoma ORR 80% | ||
|---|---|---|---|
Overview Program | Fluorouracil | Tremelimumab | MK-3475 |
Overview Company | Janssen Research & Development, LLC | AstraZeneca | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | Muscle Invasive Bladder Carcinoma | Muscle Invasive Bladder Cancer | Bladder Cancer |
Overview Indication | Advanced or Metastatic Colorectal Cancer | Hepatocellular Carcinoma | Melanoma; Non-Small Cell Lung Cancer |
Overview Phase | PHASE_3 | PHASE_3 | PHASE_2 |
Overview Status | RECRUITING | RECRUITING | RECRUITING |
MoA Mechanism | inhibits GC cell proliferation and induces apoptosis by regulating cell-cycle checkpoints and inhibiting oncogenic pathway | targeting antigens like GPC3, AFP, and PD-L1, have been engineered to address antigen | — |
MoA Biomarker | biomarker for metabolic state, B-cell/TLS-associated immune features, and vulnerability to DNA damage-based t | biomarkers for dual immune checkpoint blockade remain insufficiently defined | PD-L1) combined positive |
PK/PD Half-life | — | 16.9 h | 3 h |
PK/PD Species | Mouse, Rabbit | Mouse | Cynomolgus monkey, NHP, Mouse |
PK/PD Animal (cat.) | Mouse | Mouse | Mouse, NHP, Monkey, In vitro |
PK/PD Experiment | pharmacokinetic | PD | PD |
Toxicology Species | Rabbit | Mouse | Cynomolgus monkey, NHP, Mouse |
Toxicology Animal (cat.) | Unknown | Mouse | Mouse, NHP, Monkey, In vitro |
Toxicology Major finding | Green synthesized cobalt doped graphene quantum dots derived from Boswellia serrata for dual ligand targeted bioimaging and delivery of exemestane.. Major objective of hydrothermal method is to achieve the synthesis of Cobalt doped Graphene quantum dots (Co-GQDs) using natural precursor (Boswellia serrata gum resin). The Co-GQDs were surface engineered with folic acid (FA) and hyaluronic acid (HA)… | Interstitial lung disease associated with novel anticancer agents in non-small cell lung cancer: | pneumonitis) after switching were explored |
Clinical Primary efficacy | ORR 80% | ORR 84.6% | ORR 38% |
Clinical ORR | 80.0% | 84.6% | 38% |
Clinical Result source | ClinicalTrials.gov NCT04430738 | ClinicalTrials.gov NCT03043872 | ClinicalTrials.gov NCT02444741 |
Clinical Data Tier / Score | S · 70 | B · 70 | C · 47 |
Clinical Program phase | PHASE_3 | PHASE_3 | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) | 2026년 7월 18일 (8일 전) | 2026년 7월 9일 (18일 전 · 갱신 권장) |
추천 비교
추천 비교